Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).

ABSTRACT:

Background

Lutetium-177-DOTA-octreotate (¹⁷⁷Lu-DOTATATE) significantly increases survival and response rates in patients with grade I and grade II neuroendocrine tumors (NETs). However, survival and response rates are significantly lower in patients with bulky liver metastases. Increasing the tumor-absorbed dose in liver metastases may improve response to ¹⁷⁷Lu-DOTATATE. The LUTIA (Lutetium Intra-Arterial) study aims to increase the tumor-absorbed dose in liver metastases by intra-arterial (IA) administration of ¹⁷⁷Lu-DOTATATE, compared to conventional intravenous (IV) administration.

Methods

A multicenter, within-patient randomized controlled trial (RCT) in 26 patients with progressive, liver-dominant, unresectable grade I or grade II NET wi

SUBMITTER: Ebbers SC 

PROVIDER: S-EPMC7003409 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature